Kazakhstan Pharmaceutical Market 2026 | EAEU Entry Guide for Pharma & Nutraceuticals

A country of 20.5 million people, a GDP exceeding $300 billion, and economic growth of 6.5% in 2025 — Kazakhstan is not just another 'emerging market' to add to a watchlist. It is the largest economy in Central Asia and one of the fastest-growing pharmaceutical markets in the Eurasian region.

According to Proxima Research International (IQVIA's partner for EAEU analytics), the retail pharmaceutical market reached $411 million in Q1 2025 and 135 million units in volume. The average price per pack grew 8.5% year-on-year — a sign that the market is maturing upward, not expanding on price cuts. Imported products account for 85% of the market in value terms, meaning the shelf is open to foreign manufacturers.

According to an EY survey conducted in December 2025, the majority of market participants expect growth of 5–10% over the next two years, driven primarily by the commercial retail segment.

Healthcare investment is structural, not cyclical. The government's compulsory health insurance system (CSHI) now covers 84% of the population, and state healthcare spending for 2026 is budgeted at 2.73 trillion KZT — an increase of 162 billion over 2025. Since the launch of CSHI, average annual healthcare funding growth has run at 23.8%.

The middle class is the engine. Its share of the population has grown from 26% to 67% over the past 15 years. This translates directly into demand for branded generics, nutraceuticals, and premium OTC products.

Digital infrastructure is being built at state level. By end-2025, 92% of medical services were being processed automatically. The Ministry of Health has launched an AI-based quality management system integrated into the national healthcare payment platform. Kazakhstan's total e-commerce market grew sevenfold since 2020. Online pharma sales are an accelerating channel that is not yet saturated.

Top therapeutic categories: GI and metabolism, respiratory, systemic anti-infectives. Top OTC products: Heptral, Creon, Urosan. Top supplements: Detrimax, Fertal, Normobact.

Regional growth. Almaty and Astana dominate volume, but double-digit growth is being recorded in Mangystau, Pavlodar, Kostanay and Akmola regions — significant for distributors planning regional rollouts.

Key risk: 85% of companies surveyed by EY cite state price regulation as the primary access constraint. VAT on pharmaceuticals has been introduced from 2026, requiring portfolio pricing review.

Kazakhstan is a full EAEU member. Registration here enables simplified mutual recognition procedures across Belarus, Armenia and Kyrgyzstan — making it the strategically optimal reference state for Eurasian market entry.

Regulated as food products under sanitary legislation. No pharmaceutical licence required for distribution — the entry threshold is substantially lower than for medicinal products. Requirements include: mandatory state registration prior to market entry, laboratory testing (microbiological, toxicological, physicochemical parameters), inclusion in the EAEU unified certificate registry. A pilot programme for digital traceability labelling was launched in 2025.

Full transition to EAEU harmonised registration rules is now in effect. Classes 1–3 and IVDs; timelines range from 9–18 months, up to 24 months for complex IVDs. Devices registered under national rules before the EAEU transition deadline remain valid through certificate expiry; re-registration under national rules requires application before 31 December 2026.

Entering Kazakhstan from Europe means managing regulatory dossiers, EAEU GMP coordination, local negotiations, logistics, and pharmacovigilance — simultaneously, in a different language and timezone. Investpharm operates as a full-cycle market entry partner, not a logistics operator.

Regulatory affairs. eCTD dossier preparation in EAEU format, coordination with the National Centre for Expertise, EAEU GMP inspection facilitation, and mutual recognition procedures for subsequent EAEU market expansion.

Local office in Kazakhstan. Physical presence with a team that understands procurement cycles, pharmacy chain listing processes, and public tender logic. In Kazakhstan's state channel, relationships and local credibility matter as much as the dossier.

GDP-certified warehouse in Bratislava. All shipments originate from an EU GDP-compliant warehouse in Slovakia — full cold chain capability, complete batch documentation, and European-standard quality assurance for every delivery.

Multi-market synergy. Investpharm operates concurrently in Slovakia (EU), Moldova, and Kazakhstan (EAEU), with affiliated operations in the UAE through Afar Trade. One partner. One contract. Three regulatory frameworks.

Kazakhstan's pharmaceutical market combines macroeconomic resilience, accelerating state investment in healthcare, a consolidating retail channel, and an ambitious digital transformation agenda. Import products dominate, and international companies are only beginning to engage the market systematically.

The competitive window is open. The question is not whether Kazakhstan belongs in your market strategy — it is how quickly you act on it.

Investpharm is a Slovak pharmaceutical company with operational expertise across the EU, Moldova, Kazakhstan and the UAE. Full-cycle services: from EAEU regulatory affairs to delivery from a GDP-certified warehouse in Bratislava.

For partnership enquiries: info@investpharm.eu | investpharm.eu

Next article → FDA 2025 Breakthrough Drugs